# DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
> **NDA211868** · New Drug Application · Sponsor: EMCURE PHARMS LTD · Approved 2023-07-12
## Drug
- **FDA Application Number:** NDA211868
- **Application type:** New Drug Application
- **Brand name:** DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
- **Generic name:** Dolutegravir
- **Active ingredients:** DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** EMCURE PHARMS LTD
- **First approval:** 2023-07-12
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211868)
---
*MORVS · CC0 1.0*